Carcinoma of Unknown Primary

Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer.

PMID 24354346 · Walczyk et al., 2014 · Open in CIViC

In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T (N=35), recurrence-free survival is worse than in patients harboring one of these mutations (N=… (full text at CIViC)

PMID 25024077 · Xing et al., 2014 · Open in CIViC

In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, lo… (full text at CIViC)

PMID 18682506 · Elisei et al., 2008 · Open in CIViC

Clinical study including 219 patients with papillary thyroid cancer (PTC) to determine a correlation between the BRAF V600E mutation and poor oncological outcome. This study found that 107 of the 219 … (full text at CIViC)

PMID 16174717 · Xing et al., 2005 · Open in CIViC

BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts.

PMID 21594703 · Howell et al., 2011 · Open in CIViC

BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases.

PMID 24396464 · He et al., 2014 · Open in CIViC

V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo).

PMID 21594703 · Howell et al., 2011 · Open in CIViC

In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5% vs.… (full text at CIViC)

PMID 21882184 · Kim et al., 2012 · Open in CIViC

In transgenic mice with thyroid-specific expression of BRAF V600E, Tg-BRAF2 mice developed papillary thyroid carcinoma (PTC) in 14 of 15 animals at 12 weeks and 13 of 14 animals at 22 weeks. These tum… (full text at CIViC)

PMID 15899815 · Knauf et al., 2005 · Open in CIViC

Cell growth of several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell lines with activating BRAF mutations were insensitive, … (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

In a phase 2 trial, patients with radioiodine refractory papillary thyroid carcinoma harboring BRAF mutation were treated with dabrafenib alone or combination with trametinib. 94% patients havd BRAF V… (full text at CIViC)

Open in CIViC

In a phase 2 trial, patients with radioiodine refractory papillary thyroid carcinoma harboring BRAF mutation were treated with dabrafenib alone or combination with trametinib. 94% of patients had BRAF… (full text at CIViC)

Open in CIViC

In a single-center retrospective study of 10 patients with BRAF V600E-positive papillary thyroid carcinoma treated with dabrafenib plus trametinib, 5/10 patients (50%; 95% CI 24–76%) achieved an objec… (full text at CIViC)

PMID 40844731 · Ando et al., 2025 · Open in CIViC

A 78-year-old Chinese female patient presented with BRAF V600E-mutant metastatic pancreatic adenocarcinoma. The patient received two cycles of chemotherapy. Following the second incomplete cycle of ch… (full text at CIViC)

PMID 41367868 · Liu et al., 2025 · Open in CIViC

BRAF mutations were identified in 9% of 108 cases of high-grade colorectal neuroendocrine tumors (80% V600E). Two patients were treated with a combination of BRAF and MEK inhibition and exhibited dura… (full text at CIViC)

PMID 27048246 · Klempner et al., 2016 · Open in CIViC

In an in vitro study, K2, a papillary thyroid carcinoma cell line expressing the BRAFV600E mutation, was associated with sensitivity to dasatinib treatment. Sensitivity was determined by assessing cel… (full text at CIViC)

PMID 23729178 · Henderson et al., 2014 · Open in CIViC

Open label phase 2 (Clinical Level B) trial including patients from across the globe (USA, Italy, and the Netherlands) investigating sensitivity to Vemurafenib in patients that have BRAF V600E-positiv… (full text at CIViC)

PMID 27460442 · Brose et al., 2016 · Open in CIViC

Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort… (full text at CIViC)

PMID 27460442 · Brose et al., 2016 · Open in CIViC

In a retrospective study of 35 lung adenocarcinoma patients (with chemotherapy previously administered in 86% of patients), patients harboring a BRAF V600E mutation and treated with vemurafenib monoth… (full text at CIViC)

PMID 26200454 · Gautschi et al., 2015 · Open in CIViC

A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the … (full text at CIViC)

PMID 24987354 · Ali et al., 2014 · Open in CIViC

A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard ch… (full text at CIViC)

PMID 26490654 · Combe et al., 2015 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

In a retrospective study of 17 papillary thyroid cancer patients, patients with BRAF V600E mutation (n=6) were associated with a 47% (7/15) partial response rate and a 53% (8/15) stable disease rate.

PMID 25353071 · Dadu et al., 2015 · Open in CIViC

In a clinical trial (NCT01286753) of 55 cancer patients with BRAF V600E mutation, patients with metastatic papillary thyroid cancer (n=3) were associated with sensitivity to vemurafenib treatment. One… (full text at CIViC)

PMID 23489023 · Kim et al., 2013 · Open in CIViC

In a lung adenocarcinoma patient with brain metastases harboring BRAF V600E mutation, BRAF V600E was associated with sensitivity to vemurafenib treatment. Upon treatment with vemurafenib monotherapy, … (full text at CIViC)

PMID 24888229 · Robinson et al., 2014 · Open in CIViC

In a stage IV non-small cell lung cancer patient with a BRAF V600E mutation, who developed adenocarcinoma, BRAF V600E was associated with sensitivity to vemurafenib treatment. The patient was initiall… (full text at CIViC)

PMID 23733758 · Peters et al., 2013 · Open in CIViC

A stage IV lung adenocarcinoma patient harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient�s prior treatment regimens were complex, including radiother… (full text at CIViC)

PMID 26776917 · Myall et al., 2016 · Open in CIViC

A 42 year old man with non-smoking history presented with EGFR L858R positive lung adenocarcinoma. He was given various treatments including erlotinib and gefitinib and progressed four years later. bi… (full text at CIViC)

PMID 29074209 · Bearz et al., 2017 · Open in CIViC

In a study of 468 colorectal adenocarcinoma 61 patients had micro-satellite instability (MSI) and there was a marginally statistically significantly better prognosis for BRAF WT (n=26) patients relati… (full text at CIViC)

PMID 27302369 · Schell et al., 2016 · Open in CIViC

In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to ma… (full text at CIViC)

PMID 31157963 · Golan et al., 2019 · Open in CIViC

Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC)

PMID 34081848 · Tutt et al., 2021 · Open in CIViC

In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.0… (full text at CIViC)

PMID 25847936 · Isakoff et al., 2015 · Open in CIViC

In patients with platinum-sensitive, recurrent serous ovarian cancer with BRCA mutation, median PFS was significantly longer in patients that received olaparib as compared to placebo (11.2 vs. 4.3 mon… (full text at CIViC)

PMID 24882434 · Ledermann et al., 2014 · Open in CIViC

In this phase II study, 46 patients were enrolled (42 were evaluable; 27 gBRCA2, seven gBRCA1, six gPALB2, and two sBRCA2) and their chemotherapy was discontinued; patients then received rucaparib 600… (full text at CIViC)

PMID 33970687 · Reiss et al., 2021 · Open in CIViC

In an in vitro study, a SNU-251 cell line expressing BRCA1 W1815X truncating mutation demonstrated increased sensitivity to olaparib treatment with long-term exposure, compared to ovarian cell lines e… (full text at CIViC)

PMID 23415752 · Stordal et al., 2013 · Open in CIViC

In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to ma… (full text at CIViC)

PMID 31157963 · Golan et al., 2019 · Open in CIViC

Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC)

PMID 34081848 · Tutt et al., 2021 · Open in CIViC

In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.0… (full text at CIViC)

PMID 25847936 · Isakoff et al., 2015 · Open in CIViC

In patients with platinum-sensitive, recurrent serous ovarian cancer with BRCA mutation, median PFS was significantly longer in patients that received olaparib as compared to placebo (11.2 vs. 4.3 mon… (full text at CIViC)

PMID 24882434 · Ledermann et al., 2014 · Open in CIViC

Renal cell carcinoma (RCC) remains an intractable genitourinary malignancy. Resistance to chemotherapy or targeted therapies in RCC is presumably due to the complicated underlying molecular mechanisms… (full text at CIViC)

PMID 28391274 · Wu et al., 2017 · Open in CIViC

In a phase II trial, patients with squamous non-small cell lung cancer who had progressed at least one prior platinum-based chemotherapy with CCND1/2/3 or CDK 4 amplification were treated with palboci… (full text at CIViC)

PMID 31302234 · Edelman et al., 2019 · Open in CIViC

28 renal cell carcinoma cell lines were tested for sensitivity to CDK4/6 inhibitor Palbociclib (PD0332991). 19 were reported sensitive, and 9 resistant. 15 of the 28 cell lines had high levels of Cycl… (full text at CIViC)

PMID 23898052 · Logan et al., 2013 · Open in CIViC

Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma.

PMID 16309541 · Thomas et al., 2005 · Open in CIViC

In a phase II trial, patients with squamous non-small cell lung cancer who had progressed at least one prior platinum-based chemotherapy with CCND1/2/3 or CDK 4 amplification were treated with palboci… (full text at CIViC)

PMID 31302234 · Edelman et al., 2019 · Open in CIViC

In a phase II trial, patients with squamous non-small cell lung cancer who had progressed at least one prior platinum-based chemotherapy with CCND1/2/3 or CDK 4 amplification were treated with palboci… (full text at CIViC)

PMID 31302234 · Edelman et al., 2019 · Open in CIViC

A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors

PMID 27663592 · Au-Yeung et al., 2017 · Open in CIViC

Analysis of 5 uterine serous carcinoma (USC) primary cell lines in vitro indicated enhanced sensitivity to CDK2/9 inhibitor CYC065 in cell lines overexpressing cyclin E1 (CCNE1) in comparison to low C… (full text at CIViC)

PMID 27351214 · Cocco et al., 2016 · Open in CIViC

Elevated levels of CCNE1 mRNA has been shown to be correlated with advanced stage gastric carcinoma.

PMID 10224221 · Donnellan et al., 1999 · Open in CIViC